Testosterone Topical Gel, 1.62% Metered Pump + AndroGel (testosterone gel) 1.62% Metered-Dose Pump

Phase 3Completed
1 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Primary Hypogonadism

Conditions

Primary Hypogonadism, Hypogonadotropic Hypogonadism

Trial Timeline

Mar 1, 2014 → May 1, 2014

About Testosterone Topical Gel, 1.62% Metered Pump + AndroGel (testosterone gel) 1.62% Metered-Dose Pump

Testosterone Topical Gel, 1.62% Metered Pump + AndroGel (testosterone gel) 1.62% Metered-Dose Pump is a phase 3 stage product being developed by Amneal Pharmaceuticals for Primary Hypogonadism. The current trial status is completed. This product is registered under clinical trial identifier NCT02110368. Target conditions include Primary Hypogonadism, Hypogonadotropic Hypogonadism.

What happened to similar drugs?

20 of 20 similar drugs in Primary Hypogonadism were approved

Approved (20) Terminated (6) Active (0)
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
Duloxetine + PlaceboEli LillyApproved
Eszopiclone + PlaceboSumitomo PharmaApproved
Eszopiclone + PlaceboSumitomo PharmaApproved
RosuvastatinAstraZenecaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02110368Phase 3Completed

Competing Products

20 competing products in Primary Hypogonadism

See all competitors
ProductCompanyStageHype Score
Unfractionated heparinSinopharmPre-clinical
33
azenosertibZentalis PharmaceuticalsPhase 2
32
Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
25
REN001OnKure TherapeuticsPhase 1
11
Mavodelpar + PlaceboOnKure TherapeuticsPhase 2
25
REN001OnKure TherapeuticsPhase 2/3
20
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboSkye BiosciencePhase 2
25
Rituximab + Methotrexate + Cytarabine InjectionCelltrionPhase 2
31
Rituximab, lenalidomideCelltrionPhase 2
42
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
40
CS-3150Daiichi SankyoPre-clinical
26
Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPre-clinical
33
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
43
Combination of bempedoic acid and ezetimibeDaiichi SankyoPre-clinical
33
DS-8201a + T-DM1Daiichi SankyoPhase 3
44
Bempedoic acid and/or its fixed dose combination with ezetimibeDaiichi SankyoPre-clinical
18
Roxadustat + PlaceboAstellas PharmaPhase 3
32
Enzalutamide + ExemestaneAstellas PharmaPhase 2
35
Bocidelpar + PlaceboAstellas PharmaPhase 2
27
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
31